Generation Bio (NASDAQ:GBIO) Issues Earnings Results

Generation Bio (NASDAQ:GBIO) released its quarterly earnings results on Thursday. The company reported ($0.32) EPS for the quarter, missing analysts’ consensus estimates of ($0.31) by ($0.01), Zacks reports. Generation Bio had a negative return on equity of 104.85% and a negative net margin of 782.86%. The firm had revenue of $4.19 million for the quarter, compared to analyst estimates of $2.92 million.

Generation Bio Price Performance

NASDAQ:GBIO opened at $0.48 on Friday. The firm has a market capitalization of $32.06 million, a PE ratio of -0.22 and a beta of 2.72. The business’s fifty day moving average price is $0.74 and its 200 day moving average price is $1.53. Generation Bio has a 12 month low of $0.47 and a 12 month high of $4.65.

Insider Buying and Selling at Generation Bio

In other news, Director Anthony G. Quinn acquired 85,000 shares of the company’s stock in a transaction on Monday, January 13th. The shares were bought at an average price of $0.97 per share, with a total value of $82,450.00. Following the completion of the acquisition, the director now owns 299,286 shares in the company, valued at $290,307.42. This trade represents a 39.67 % increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. 21.10% of the stock is currently owned by insiders.

Analysts Set New Price Targets

A number of research analysts have commented on GBIO shares. Needham & Company LLC restated a “buy” rating and set a $8.00 price target on shares of Generation Bio in a research note on Friday. Wedbush reaffirmed an “outperform” rating and set a $5.00 price objective on shares of Generation Bio in a research report on Friday.

Generation Bio Company Profile

Generation Bio Co develops non-viral genetic medicines for the treatment of rare and prevalent diseases. The company develops cell-targeted lipid nanoparticle (ctLNP) platform, a modular delivery system for nucleic acids to avoid off-target clearance by the liver and spleen that enables ctLNPs to persist in systemic circulation, which allows for highly selective and potent ligand-driven targeting to specific tissues and cell types; and novel immune-quiet DNA (iqDNA) to enable long-lasting high levels of gene expression from non-integrating episomes and avoids innate immune sensors that have long prevented DNA from use in non-viral systems.